SenzaGen Investor Relations Material
Latest events
Q4 2023
SenzaGen
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from SenzaGen
Access all reports
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers modified human cell lines that can be induced to react with a wide variety of chemicals and cell genes that may be activated by specific substances. SenzaGen AB was incorporated in 2000 and is based in Lund, Sweden. As of February 19, 2016, SenzaGen AB operates as a subsidiary of Ascendis Pharma A/S.
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden